ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

    NEXT STORY
    Clinical Trial Materials and Supplies Market to Reach $25.9 billion by 2025- Exclusive Report by Meticulous Research®
    PREV STORY
    Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2018

    Second Product Program, NZV930 Enters Clinical DevelopmentCAMBRIDGE, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- ...

    author_avatar
    NASDAQ Market News

    Summit Therapeutics Appoints Ralf Rosskamp, MD, as Chief Medical Officer

    OXFORD, United Kingdom, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), ...

    author_avatar
    NASDAQ Market News

    Otsuka and Lundbeck announce improvement of agitation symptoms related to Alzheimer’s-type dementia following treatment with brexpiprazole relative to placebo

    Valby, Denmark, 2017-05-02 09:10 CEST (GLOBE NEWSWIRE) -- Valby, Denmark, 2 May 2017 - ...

    author_avatar
    NASDAQ Market News